News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

ICR Logo
Lower risk of serious side-effects in trials of new targeted drugs

07/08/12

Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
ICR Logo
New evidence found for inheritability of common leukaemia

18/07/12

Scientists at The Institute of Cancer Research (ICR) in London have identified a heritable gene variant associated with an increased risk of developing chronic lymphocytic leukaemia (CLL).
ICR Logo
Obesity may affect response to breast cancer treatment

16/07/12

Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.
ICR Logo
Cancer treatment progress: Two promising new drugs revealed

12/07/12

Scientists at The Institute of Cancer Research have this week revealed promising early results from two exciting new targeted cancer drug
ICR Logo
Drug’s ‘double hit’ overcomes leukaemia resistance

12/07/12

A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, led by the ICR, is published today in the journal Leukaemia.
ICR Logo
Scientists develop new strategy to overcome drug-resistant childhood cancer

11/07/12

A new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment.
ICR Logo
'Master switch' experimental drug could treat different cancers

10/07/12

A unique multi-target experimental drug could treat a range of cancer types, according to research led by the ICR and published in Clinical Cancer Research today.
ICR Logo
Pan-European project aims to screen patients for hidden cancer cells

04/07/12

Scientists across Europe are to collaborate on a €6m project to develop a technique of screening a patient’s entire blood volume for cancer cells that have evaded treatment.
ICR Logo
Cancer drug discoverer honoured with global entrepreneurship award

01/07/12

Professor Paul Workman has won a global award recognising his success at taking pioneering drugs out of the laboratory and into commercial development for the ultimate benefit of patients worldwide.
ICR Logo
New way to control cancer blood supply discovered

28/06/12

An entirely new way to control the development of blood vessels has been discovered by scientists, which could lead to improved treatment of cancer, heart disease and eye disease, with fewer side effects. The results are published today in the journal Blood.
ICR Logo
More UK men given access to abiraterone

27/06/12

Even more men are set to benefit from the prostate cancer drug abiraterone after it was approved for NHS use in Northern Ireland.
ICR Logo
Landmark study describes long-term risk of breast cancer from lymphoma treatment

25/06/12

New research from the ICR identifies the personalised breast cancer risk for women treated for Hodgkin lymphoma.

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.